Multi-analyte liquid biopsies for molecular pathway guided personalised treatment selection in advanced refractory cancers: A clinical utility pilot study

Accurate identification of Glial Malignancies from Peripheral Blood


(2022)

Accurate screening for early-stage breast cancer by detection and profiling of circulating tumor cells

(2022)

Extensive Tumor Profiling in Primary Neuroendocrine Breast Cancer Cases as a role model for personalized treatment in rare and aggressive cancer types

(2022)

Excellent Response with Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma with PIK3CA Mutation and High Androgen Receptor Expression (2021)

Development and validation of a multigene variant profiling assay to guide targeted and immunotherapy selection in solid tumors

(2021)

Improved Treatment Outcomes by Using Patient Specific Drug Combinations in Mammalian Target of Rapamycin Activated Advanced Metastatic Cancers

(2021)

Angiogenesis Inhibitors in Personalized Combination Regimens for the Treatment of Advanced Refractory Cancers

(2021)

Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk

(2020)

Evaluation of Circulating Tumor Cell Clusters for Pan-Cancer Noninvasive Diagnostic Triaging

(2020)

A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer

(2020)

Clinical utility of circulating tumor‑associated cells to predict and monitor chemo‑response in solid tumors

(2020)

Long Overall Survival in a Case of Refractory Stage IV Squamous Cell Carcinoma of Lung Treated with Personalized De Novo Combination Regimen

(2020)

Circulating ensembles of tumor-associated cells: A redoubled new systemic hallmark of cancer

(2019)

Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial

(2019)

Adaptive, Iterative, Long-Term Personalized Therapy Management in a Case of Stage IV Refractory NSCLC

(2019)